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Abstract
Objectives: Outpatient treatment of acute venous thromboembolism (VTE) requires the selection of
patients with a low risk of bleeding during the ﬁrst few weeks of anticoagulation. The accuracy of four
systems, originally derived for predicting bleeding in VTE treated with vitamin K antagonists (VKAs),
was assessed in VTE patients treated with rivaroxaban.
Methods: All patients treated with rivaroxaban in the multinational EINSTEIN deep vein thrombosis
(DVT) and pulmonary embolism (PE) trials were included. Major bleeding was deﬁned as ≥2 g/dL
drop in hemoglobin or ≥2-unit blood transfusion, bleeding in critical area, or bleeding contributing to
death. The authors examined the incidence of major bleeding in patients with low-risk assignment by
the systems of Ruiz-Gimenez et al. (score = 0 to 1), Beyth et al. (score = 0), Kuijer et al. (score = 0),
and Landefeld and Goldman. (score = 0). For clinical relevance, the deﬁnition of low risk for all scores
except Kuijer includes all patients < 65 years with no prior bleeding history and no comorbid
conditions (current cancer, renal insufﬁciency, diabetes mellitus, anemia, prior stroke, or myocardial
infarction).
Results: A total of 4,130 patients (1,731 with DVT only, 2,399 with PE with or without DVT) were treated
with rivaroxaban for a mean (SD) duration of 207.6 (95.9) days. Major bleeding occurred in 1.0% (40
of 4,130; 95% conﬁdence interval [CI] = 0.7% to 1.3%) overall. Rates of major bleeding for low-risk
patients during the entire treatment period were similar: Ruiz-Gimenez et al., 12 of 2,622 (0.5%; 95%
CI = 0.2% to 0.8%); Beyth et al., nine of 2,249 (0.4%; 95% CI = 0.2% to 0.8%); Kuijer et al., four of 1,186
(0.3%; 95% CI = 0.1% to 0.9%); and Landefeld and Goldman, 11 of 2,407 (0.5%; 95% CI = 0.2% to 0.8%).
At 30 days, major bleed rates for low-risk patients were as follows: Ruiz-Gimenez et al., ﬁve of 2,622
(0.2%; 95% CI = 0.1% to 0.4%); Beyth et al., ﬁve of 2,249 (0.2%; 95% CI = 0.1% to 0.5%); Kuijer et al.,
three of 1,186 (0.3%; 95% CI = 0.1% to 0.7%); and Landefeld and Goldman, seven of 2,407 (0.3%; 95%
CI = 0.1% to 0.6%). No low-risk patient had a fatal bleed.
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Conclusions: Four scoring systems that use criteria obtained in routine clinical practice, derived to
predict low bleeding risk with VKA treatment for VTE, identiﬁed patients with less than a 1% risk of
major bleeding during full-course treatment with rivaroxaban.
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Three systematic reviews in patients with pul-monary embolism (PE) have suggested a verylow rate of recurrent venous thromboembolism
(VTE) associated with home treatment in patients identi-
ﬁed as low risk by validated prognostic scores (e.g., Pul-
monary Embolism Severity Index, Hestia criteria).1–3
However, there is uncertainty about the risk of major
bleeding during the initial treatment as the third sys-
tematic review observed a high relative risk of major
bleeding, albeit statistically nonsigniﬁcant (relative risk =
4.91, 95% conﬁdence interval [CI] = 0.24 to 101.57;
p = 0.30).3
The transformation of the payment structure for
health care in the United States toward a ﬁxed-sum
model (e.g., accountable care organization) provides an
economic incentive to treat as many VTE patients as
safely possible at home. The commercial introduction of
direct oral anticoagulants for treatment of VTE has
facilitated the ability to treat patients with acute symp-
tomatic deep vein thrombosis (DVT) and PE in the out-
patient setting (clinic, emergency department, ofﬁce or
urgent care) without hospitalization.4 However, reluc-
tance for outpatient treatment could be based on the
uncertainty about the risk of major bleeding for acute
patients treated with direct oral anticoagulants. Accord-
ingly, validated clinical criteria are needed to help clini-
cians select patients with DVT and PE who are not only
at a low risk for recurrent VTE, but also at a low risk of
major bleeding.
At least four scoring systems (Landefeld and Gold-
man,5 Beyth et al.,6 Kuijer et al.,7 and Ruiz-Gimenez
et al.8) have been derived and initially validated to pre-
dict risk of major bleeding after starting vitamin K
antagonist (VKA) treatment for VTE.5–8 All of these tools
share common predictors, including age, comorbid con-
ditions and, with exception of Kuijer et al., prior bleed-
ing history. Details of the individual scoring systems are
provided in Table 1. To our knowledge, no bleeding
score has been tested in patients treated with direct oral
anticoagulants.
Taking advantage of data from the EINSTEIN DVT
and EINSTEIN PE clinical trials, we sought to measure
the incidence of major bleeding for patients treated with
rivaroxaban who had a low risk for major bleeding
according to these scores.9–11 In addition, we present
these incidences for patients who did not have low
bleeding risk scores and for patients who were treated
with enoxaparin/VKAs.
METHODS
Study Design
This was a secondary analysis of data pooled from
EINSTEIN DVT and EINSTEIN PE, which were
multinational, phase III randomized, open-label trials.
Both trials (NCT numbers 00439777 and 00440193) were
sponsored by Bayer Healthcare and Ortho-McNeil.9–11
Protocols were approved by institutional review boards,
and patients provided written informed consent.
Study Setting and Population
Patients were potentially eligible if they had objectively
conﬁrmed symptomatic DVT and/or PE. Patients were
excluded for the following reasons: 1) received a thera-
peutic dose of low-molecular-weight heparin, fonda-
parinux, or unfractionated heparin for more than
48 hours; 2) received more than a single dose of a VKA;
3) the qualifying VTE having been treated with
thrombectomy, a vena cava ﬁlter, or ﬁbrinolytic therapy;
4) any contraindication listed in the local labeling of
enoxaparin, warfarin, or acenocoumarol; 5) an esti-
mated creatinine clearance < 30 mL/min; 6) clinically
signiﬁcant liver disease (e.g., acute hepatitis, chronic
active hepatitis, or cirrhosis); 7) systolic blood pressure
greater than 180 mm Hg or diastolic blood pressure
greater than 110 mm Hg; 8) childbearing potential with-
out proper contraceptive measures, pregnancy, or
breast-feeding; 9) concomitant use of strong cytochrome
P-450 3A4 inhibitors (e.g., human immunodeﬁciency
virus protease inhibitors or systemic ketoconazole) or
inducers (e.g., rifampicin, carbamazepine, or phenytoin);
and 10) life expectancy of less than 3 months.
Study Protocol
Patients assigned to rivaroxaban were given 15 mg
orally twice daily for the ﬁrst 3 weeks, followed by
20 mg once daily for the intended treatment duration of
3, 6, or 12 months, as determined locally. Patients who
were assigned to standard therapy received subcuta-
neous enoxaparin, 1.0 mg/kg body weight twice daily,
and either warfarin or acenocoumarol, started within
48 hours after randomization. Enoxaparin was discon-
tinued when the international normalized ratio (INR)
was 2.0 or more for two consecutive days and the
patient had received at least 5 days of enoxaparin treat-
ment. The dose of the VKA was adjusted to maintain an
INR of 2.0 to 3.0. The INR was determined at least once
per month.
Surveillance for Bleeding . In both studies, patients
were followed for the intended treatment duration and
seen at ﬁxed intervals that were identical for the
rivaroxaban and comparison groups, at which time a
checklist that included speciﬁc questions about bleeding,
including its location, severity, and treatment, was com-
pleted. Patients were instructed to report to the study
center immediately if any bleeding occurred. Bleed-
ing was deﬁned as major if it was clinically overt and
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associated with a decrease in hemoglobin level of
≥2.0 g/dl; if bleeding led to the transfusion of ≥2 units of
red cells; or if bleeding was intracranial or retroperi-
toneal, occurred in another critical site, or contributed
to death.12 Clinically relevant nonmajor bleeding was
deﬁned as overt bleeding that did not meet the criteria
for major bleeding but was associated with medical
intervention, unscheduled contact with a physician,
interruption or discontinuation of study drug, or dis-
comfort or impairment of activities of daily life.
Data Analysis
Data for the four bleeding scores were collected
directly from data sourced from case report forms for
each patient as recorded in the locked database. The
hematocrit, graded as abnormal when lower than
30%, as required by the Landefeld and the Beyth risk
scores, was not collected in the EINSTEIN studies and
operationalized as a hemoglobin below 10 g/dL. Any
missing data were assumed to fall in the normal or
negative range for the purpose of computing each
score. Data were extracted using scripts written in
SAS (version 9.2). Success was deﬁned as an upper
limit of the 95% exact CI of the incidence of major
bleeding below 1.0%. Bleeding rates were calculated
both for the entire treatment period and for the ﬁrst
30 days.
RESULTS
In the pooled sample, a total of 8,281 patients with valid
informed consent were randomized at 314 sites in 38
countries.11 Figure 1 shows the ﬂow of patients, of
whom 4,130 received treatment with rivaroxaban and
4,116 enoxaparin/VKA, for mean (SD) durations of
207.6 (95.9) and 203.8 (97.4) days, respectively.
Table 1 shows the distribution of the components of the
four scoring systems, including the numbers of missing
data. No patients had recent bleeding as this was an
exclusion to enrollment. Table 2 shows the demographic
features and past medical history of patients with DVT
only (EINSTEIN DVT) or PE with or without DVT (EIN-
STEIN PE) and the pooled sample. The proportions of
patients with older age, recent surgery, active cancer,
and immobility were not different between the treat-
ment groups and between the EINSTEIN DVT and EIN-
STEIN PE studies.
Overall, major bleeding occurred in 40 of 4,130 (1.0%,
95% CI = 0.7% to 1.3%) patients treated with rivaroxa-
ban during the entire study period and occurred at a
mean (SD) of 69 (72.5) days (median 43 days,
interquartile range = 7.5–117.5 days) of treatment. Of
the patients treated with rivaroxaban, 2,622 (63.6%),
2,249 (54.5%), 1,186 (28.7%), and 2,407 (58.3%) qualiﬁed
for the low-risk categories according to the scoring
Table 1
Predictor Variables for Major Bleeding and Their Frequency in the Entire Cohort
Variable Points N (+)* N (–)† Missing Values
Ruiz-Gimenez et al.8 (score = 0–1 low risk)
Age > 75 yr 1 1,283 (15.5) 6,998 (84.5) 0
Active cancer at baseline 1 462 (5.6) 7,819 (94.4) 0
Clinically overt PE 1 4,809 (58.1) 3,472 (41.9) 0
Recent major bleeding 2 0 8,281 (100%) 0
Creatinine level > 1.2 mg/dL 1.5 915 (11.1) 7,278 (87.9) 88 (1.1)
Anemia (hemoglobin < 12 g/dL for women and < 13 g/dL for men) 1.5 1,791 (21.6) 6,408 (77.4) 82 (1.0)
Beyth et al.6 (score = 0 low risk)
Age ≥ 65 yr 1 3,085 (37.3) 5,196 (62.8) 0
History of stroke 1 222 (2.7) 8,059 (97.3) 0
History of gastrointestinal bleeding 1 73 (0.9) 8,208 (99.1) 0
Serious comorbid condition (one or more of the following) 1
Renal insufficiency (serum creatinine > 1.5 mg/dL) 1 194 (2.3) 7,999 (96.6) 88 (1.1)
Recent myocardial infarction 1 0 8,081 (100%) 0
Severe anemia (hemoglobin < 10 g/dL) 1 280 (3.4) 7,919 (95.6) 82 (1.0)
Diabetes mellitus at baseline 1 840 (10.1) 7,441 (89.9) 0
Kuijer et al.7 (score = 0 low risk)
Age ≥ 60 yr 1.6 3,969 (48.0) 4,312 (52.1) 0
Sex (female) 1.3 3,765 (45.5) 4,516 (54.5) 0
Malignancy 2.2 462 (5.6) 7,819 (94.4) 0
Landefeld and Goldman5 (score = 0 low risk)
Age ≥ 65 yr 1 3,085 (37.3) 5,196 (62.8) 0
History of stroke (one of the following) 1 or 2
History of stroke (either current or past) 1 223 (2.7) 8,465 (97.3) 0
History of stroke (both current and past) 2 1 (0.01) 8,280 (99.9) 0
History of gastrointestinal bleeding 1 73 (0.9) 8,208 (99.1) 0
Serious comorbid condition (one or more of the following) 1
Renal insufficiency (serum creatinine > 1.5 mg/dL) 1 194 (2.3) 7,999 (96.6) 88 (1.1)
Recent myocardial infarction 1 0 8,281 (100%) 0
Severe anemia (hemoglobin < 10 g/dL) 1 280 (3.4) 7,919 (95.6) 82 (1.0)
Atrial fibrillation 1 190 (2.3) 8,091 (97.7) 0
*Number with the feature.
†Number lacking the feature (% of 8,281).
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systems of Ruiz-Gimenez et al., Beyth et al., Kuijer et al.,
and Landefeld and Goldman, respectively. The inci-
dences of major bleeding for the entire treatment period
in these patients were as follows: Ruiz-Gimenez et al.,
12 of 2,622 (0.5%, 95% CI = 0.2% to 0.8%); Beyth et al.,
nine of 2,249 (0.4%, 95% CI = 0.2% to 0.8%); Kuijer
et al., four of 1,186 (0.3%, 95% CI = 0.1% to 0.9%); and
Landefeld and Goldman, 11 of 2,407 (0.5%, 95%
CI = 0.2% to 0.8%). Incidences of major bleeding during
the entire treatment period in other risk categories and
in the enoxaparin/VKA group are given in Table 3.
None of the low-risk rivaroxaban-treated patients by
any system had a fatal bleed. Incidences of major bleed-
ing in low-risk patients at 30 days were as follows:
Ruiz-Gimenez et al., ﬁve of 2,622 (0.2, 95% CI = 0.1% to
0.4%); Beyth et al., ﬁve of 2,249 (0.2, 95% CI = 0.1%
to 0.5%); Kuijer et al., three of 1,186 (0.3, 95% CI = 0.1%
to 0.7%); and Landefeld and Goldman, seven of 2,407
(0.3, 95% CI = 0.1% to 0.6%). Incidences of major bleed-
ing in the ﬁrst 30 days in other risk categories and in
the enoxaparin/VKA group are given in Table 3. Only
one low-risk enoxaparin/VKA-treated patient had fatal
bleeding.
The rates of clinically relevant nonmajor bleeding for
the different risk categories according to time at risk
(entire study period, ﬁrst 30 days) are shown in Table 4.
In general, patterns were similar to the results observed
for major bleeding and the risks of clinically relevant
Figure 1. Flow diagram showing numbers of patients enrolled and their bleeding-related outcomes in each treatment arm.
VKA = vitamin K antagonist.
Table 2
Demographic and Clinical Characteristics
Characteristic
EINSTEIN DVT EINSTEIN PE EINSTEIN Pooled
Rivaroxaban
Heparin/
VKA Rivaroxaban
Heparin/
VKA Rivaroxaban
Heparin/
VKA
(N = 1,731) (N = 1,718) (N = 2,419) (N = 2,413) (N = 4,150) (N = 4,131)
Male sex 993 (57.4) 967 (56.3) 1309 (54.1) 1247 (51.7) 2302 (55.5) 2214 (53.6)
Age (yr) 55.8  16.4 56.4  16.3 57.9  17.3 57.5  17.2 57.0  17.0 57.0  16.8
Race (white) 1,327 (76.7) 1,319 (76.8) 1,585 (65.5) 1,587 (65.8) 2,912 (70.2) 2,906 (70.3)
Recent surgery or trauma 338 (19.5) 335 (19.5) 415 (17.2) 398 (16.5) 753 (18.1) 733 (17.7)
Previous VTE 336 (19.4) 330 (19.2) 455 (18.8) 489 (20.3) 791 (19.1) 819 (19.8)
Active cancer 118 (6.8) 89 (5.2) 114 (4.7) 109 (4.5) 232 (5.6) 198 (4.8)
Immobilization 265 (15.3) 260 (15.1) 384 (15.9) 380 (15.7) 649 (15.6) 640 (15.5)
Known thrombophilic condition 107 (6.2) 116 (6.8) 138 (5.7) 121 (5.0) 245 (5.9) 237 (5.7)
Unprovoked VTE 1,055 (60.9) 1,083 (63.0) 1,566 (64.7) 1,551 (64.3) 2,621 (63.1) 2,634 (63.8)
Duration of treatment (days)* 193.6  89.3 187.5  92.5 216.3  98.7 214.3  98.9 207.6  95.9 203.8  97.4
Data are shown as n (%) or mean  SD.
*Duration of actual study treatment after randomization until end of treatment (safety population).
DVT = deep venous thrombosis; PE = pulmonary embolism; VKA = vitamin K antagonist; VTE = venous thromboembolism.
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nonmajor bleeding were lowest in those patients quali-
fying for “low risk,” according to the scoring system.
DISCUSSION
Patients with VTE who were treated with rivaroxaban,
and who were at low risk for major bleeding based on
scores developed for bleeding during VKA treatment,
had no fatal bleeding and a low incidence of major
bleeding, with the upper limit of the 95% CI excluding
an incidence of higher than 1%. This result was
observed for both the initial 30-day and the entire treat-
ment period and was consistent among all four evalu-
ated bleeding risk scoring systems. The scoring system
according to Ruiz-Giminez et al. classiﬁed the highest
number of patients as low risk and had the lowest inci-
dence of major bleeding during the initial 30 days of
treatment.
From a clinician’s stance, the important message of
this analysis is that VTE patients under age 65 years
with normal renal function, no anemia or history of
overt bleeding, and no history of cancer or stroke, have
a low 30-day risk to develop major bleeding when trea-
ted with rivaroxaban. The criteria for all scores can be
obtained at the bedside and from routinely performed
laboratory studies (complete blood count and renal
function studies). Interestingly, the incidences of major
bleeding in all low-risk categories of the four scoring
systems were consistently lower in rivaroxaban recipi-
ents compared to those receiving standard anticoagula-
Table 4
Rate of Clinically Relevant Nonmajor Bleeding According to Score, Observation Period, and Treatment
System
Score
Points
Rivaroxaban H/VKA
Subjects
per Score
Category,
n/N (%)
(N = 4,130)
Number During
Days 1–30
(%; 95% CI)
Number
During Entire
Study Period
(%; 95% CI)
Subjects
per Score
Category,
n/N (%)
(N = 4,116)
Number During
Days 1–30
(%; 95% CI)
Number During
Entire Study
Period
(%; 95% CI)
Ruiz-
Gimenez
et al.8
Low (0–1) 2,622 (63.6) 88 (3.4; 2.7–4.1) 180 (6.9; 5.9–7.8) 2,638 (64.1) 88 (3.3; 2.7–4.0) 207 (7.8; 6.8–8.9)
Moderate
(1.5–2)
569 (13.8) 31 (5.5; 3.5–7.3) 56 (9.8; 7.4–12.3) 617 (15.0) 28 (4.5; 2.9–6.2) 57 (9.2; 6.9–11.5)
High (>2) 939 (22.7) 67 (7.1; 5.4–8.7) 121 (12.9; 10.7–15.0) 861 (20.9) 40 (4.7; 3.2–6.1) 93 (10.8; 8.7–12.9)
Beyth
et al.6
Low (0) 2,249 (54.5) 79 (3.5; 2.7–4.2) 159 (7.1; 5.6–7.7) 2,274 (55.2) 63 (2.8; 2.1–3.4) 169 (7.4; 5.9–8.0)
Moderate
(1–2)
1,850 (44.8) 105 (5.7; 4.4–6.5) 194 (10.5; 8.3–10.8) 1,816 (44.1) 91 (5.0; 3.9–5.8) 185 (10.2; 8.0–10.6)
High (>2) 31 (0.8) 2 (6.5; 0.7–20.2) 4 (12.9; 3.2–26.7) 26 (0.6) 2 (7.7; 0.9–23.5) 3 (11.5; 2.2–27.4)
Kuijer
et al.7
Low (0) 1,186 (28.7) 31 (2.6; 1.7–3.6) 65 (5.5; 4.0–6.6) 1,157 (28.1) 27 (2.3; 1.5–3.3) 68 (5.9; 4.3–7.0)
Moderate
(1–3)
2,726 (66.0) 140 (5.1; 4.1–5.7) 267 (9.8; 7.9–10.0) 2,778 (67.5) 119 (4.3; 3.4–4.9) 268 (9.6; 7.8–9.9)
High (≥3) 218 (5.3) 15 (6.9; 3.6–10.4) 25 (11.5; 6.8–14.8) 181 (4.4) 10 (5.5; 2.5–9.4) 21 (11.6; 6.6–15.5)
Landefeld
and
Goldman8
Low (0) 2,407 (58.3) 90 (3.7; 2.9–4.4) 175 (7.3; 5.8–7.8) 2,412 (58.6) 70 (2.9; 2.2–3.5) 180 (7.5; 6.0–8.0)
Moderate
(1–2)
1,694 (41.0) 93 (5.5; 4.2–6.3) 177 (10.4; 8.2–10.9) 1,679 (40.8) 82 (4.9; 3.7–5.7) 173 (10.3; 8.1–10.8)
High (>2) 29 (0.7) 3 (10.3; 2.0–25.0) 5 (17.2; 5.0–31.1) 25 (0.6) 4 (16.0; 3.9–31.7) 4 (16.0; 3.9–31.7)
Table 3
Rate of Major Bleeding According to Score, Observation Period, and Treatment
System Score Points
Rivaroxaban H/VKA
Subjects
per Score
Category,
n (%)
(N = 4,130)
Number
During Days
1–30
(%; 95% CI)
Number
During Entire
Study Period
(%; 95% CI)
Subjects
per Score
Category,
n (%)
(N = 4,116)
Number
During
Days 1–30
(%; 95% CI)
Number During
Entire Study
Period
(%; 95% CI)
Ruiz-
Gimenez
et al.8
Low (0–1) 2,622 (63.6) 5 (0.2; 0.1–0.4) 12 (0.5; 0.2–0.7) 2,638 (64.1) 9 (0.3; 0.2–0.7) 25 (0.9; 0.5–1.3)
Moderate (1.5–2) 569 (13.8) 5 (0.9; 0.3–2.0) 8 (1.4; 0.4–2.4) 617 (15.0) 10 (1.6; 0.8–2.9) 15 (2.4; 1.2–3.6)
High (>2) 939 (22.7) 7 (0.7; 0.3–1.5) 20 (2.1; 1.2–3.1) 861 (20.9) 17 (2.0; 1.2–3.1) 32 (3.7; 2.4–5.0)
Beyth
et al.6
Low (0) 2,249 (54.5) 5 (0.2; 0.1–0.5) 9 (0.4; 0.2–0.8) 2,274 (55.2) 7 (0.3; 0.1–0.6) 18 (0.8; 0.5–1.2)
Moderate (1–2) 1,850 (44.8) 12 (0.6; 0.3–1.1) 31 (1.7; 1.1–2.3) 1,816 (44.1) 27 (1.5; 1.0–2.1) 52 (2.9; 2.1–3.6)
High (>2) 31 (0.8) 0 0 26 (0.6) 2 (7.7; 0.9–23.5) 2 (7.7; 0.9–23.5)
Kuijer
et al.7
Low (0) 1,186 (28.7) 3 (0.3; 0.1–0.7) 4 (0.3; 0.1–0.9) 1,157 (28.1) 4 (0.3; 0.1–0.9) 8 (0.7; 0.3–1.3)
Moderate (1–3) 2,726 (66.0) 12 (0.4; 0.2–0.8) 33 (1.2; 0.8–1.7) 2,778 (67.5) 25 (0.9; 0.6–1.3) 56 (2.0; 1.5–2.6)
High (≥3) 218 (5.3) 2 (0.9; 0.1–3.2) 3 (1.4; 0.3–3.9) 181 (4.4) 7 (3.9; 1.5–7.5) 8 (4.4; 1.8–8.2)
Landefeld
and
Goldman5
Low (0) 2,407 (58.3) 7 (0.3; 0.1–0.6) 11 (0.5; 0.2–0.8) 2,412 (58.6) 7 (0.3; 0.1–0.6) 18 (0.7; 0.4–1.2)
Moderate (1–2) 1,694 (41.0) 10 (0.6; 0.3–1.1) 29 (1.7; 1.1–2.4) 1,679 (40.8) 27 (1.6; 1.0–2.3) 51 (3.0; 2.2–3.9)
High (>2) 29 (0.7) 0 0 25 (0.6) 2 (8.0; 0.9–24.3) 3 (12.0; 2.3–28.2)
H/VKA = heparin/vitamin K antagonist.
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tion with enoxaparin, followed by VKA. In this latter
group, the upper limit of the 95% CI of major bleeding
in the low-risk categories of the four scores did not
exclude an incidence of major bleeding of more than
1%, despite the relative large number of patients in
these categories.
In current practice, physicians admit most patients
with acute PE diagnosed in the outpatient or emer-
gency care setting.13 However, it should be realized that
many patients who have acute symptomatic DVT,
including those who are currently treated on an outpa-
tient basis, may also have concomitant asymptomatic
PE.14 Indeed, there are risk scores to identify PE
patients at low risk of recurrence who might be treated
at home. In an unselected cohort of 291 patients with
PE, seven (2.4%) deteriorated during the ﬁrst 5 days
primarily due to bleeding on heparin-VKA.15 The cur-
rent analysis suggests that the application of a simple
bleeding risk score could reduce this proportion sub-
stantially. Strengths of our analyses include the
prospective data collection, monitoring for source veri-
ﬁcation, completeness of follow-up, and the indepen-
dent assessment of outcomes.
LIMITATIONS
Limitations include the fact that this analysis, despite
prospective data collection, was deﬁned retrospectively
and patients were not managed based on their bleeding
risk scores. In addition, baseline data were missing in a
fraction of patients for hemoglobin and creatinine, and
we assumed that these values in those patients were
normal. This constitutes a conservative bias. Moreover,
some items of the bleeding risk score were not speciﬁ-
cally asked for but were part of the elicited general
medical history and were assumed to be present or
absent based on this information only, which could
have added noise. Finally, we analyzed major bleeding
during the ﬁrst 30 days of treatment and the entire
treatment period, while physicians for their decision
making might be most interested in major bleeding that
occurs very early during treatment. It should be noted
that all four scoring systems only require standard clini-
cal data available from the patient or medical records.
Potential limitations to adoption include the fact that
these data represent the result of patients who con-
sented to participate in a randomized trial and were
then monitored closely as part of the study protocol. It
is possible that the EINSTEIN sample has fewer comor-
bidities and higher compliance rate than would occur in
a real-world setting. For example, the Ruiz-Gimenez
score was ≤1 in 64% (95% CI = 63% to 65%) of all
patients in the present study, which appears to be sig-
niﬁcantly higher than the 44% (95% CI = 43% to 46%)
who were low risk in the RIETE registry.8 Additionally,
the present data do not assess risk of bleeding in later
years of treatment.
CONCLUSIONS
All four scoring systems derived to predict low bleeding
risk with vitamin K antagonist treatment excluded a
higher than 1% risk of major bleeding in the low-risk
category within the entire treatment period with
rivaroxaban. The Ruiz-Gimenez et al. score ≤ 1 occurred
in the largest fraction of patients and had the lowest
rate of major bleeding at 30 days. This score could be
used to supplement other criteria to select venous
thromboembolism patients at low risk for complications
for outpatient treatment with rivaroxaban
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